Reported about 5 hours ago
Hims & Hers Health Inc. saw a significant surge in its stock price, rising as much as 18%, following news of President-elect Donald Trump's nomination of Marty Makary to lead the FDA. Analysts from Hunterbrook Media believe Makary could be a strong ally for the company, which has been selling compounded weight loss drugs amid shortages of FDA-approved alternatives. Despite the stock's impressive performance this year, with a rise of over 200%, analysts remain largely cautious, with many suggesting a hold or sell rating.
Source: YAHOO